Two-Way Traffic: When Eye Drops Go Systemic and Systemic Drugs Hit the Eye
It is tempting to think of the eye as a sealed compartment — that a drop you place on the surface stays in the eye, and a tablet you swallow never reaches it. Both assumptions are wrong, and each has killed or blinded patients. A drop of timolol can slow an asthmatic's heart and close their airways. A tablet taken for years for lupus can quietly destroy the retina. The eye and the body are in constant two-way traffic, and a clinician who forgets it will miss the diagnosis in both directions. This chapter is the map; the deep dives into each toxicity live in the Ocular Drug Toxicity subtopic.
An 82-year-old man with mild COPD is started on timolol drops for newly diagnosed glaucoma — one drop to each eye, twice a day. It seems the safest of interventions: a tiny volume, applied to the surface of the eye, nowhere near the lungs or heart. Three weeks later he is in the emergency department, wheezing, his pulse a sluggish 44. The cardiology team hunts for a cause; nobody thinks to ask about eye drops, because a drop "couldn't possibly" do this. But it can and it did: the timolol drained down his tear duct, into his nose, and straight into his bloodstream — a non-selective beta-blocker delivered by an unintended route, bypassing the liver entirely. Stop the drops and he recovers. The lesson is uncomfortable: the most systemically dangerous drug this man was taking was the one nobody counted as a drug at all.
The eye is not a sealed box
The tear that leaves the eye does not evaporate — it drains into you. Only a fraction of an eye drop is absorbed through the cornea into the eye itself. The rest spills over the lid margin and drains through the puncta into the nasolacrimal duct, onto the highly vascular mucosa of the nose and throat, and from there directly into the systemic circulation. This is the crucial pharmacological point, covered in full in the Eye-Drop Pharmacology chapter: nasolacrimal absorption bypasses the liver's first-pass metabolism entirely. A drug that would be largely inactivated if swallowed can arrive in the blood almost intact when it drains from the eye. The surface area is small, but for potent molecules — a beta-blocker, an alpha-2 agonist — small is more than enough.
Direction one: eye drops that go systemic
Topical beta-blockers are the classic — and most dangerous — offenders. Timolol, still a workhorse of glaucoma therapy (see the Glaucoma chapter), is a non-selective beta-blocker. Once in the circulation it does everything a systemic beta-blocker does: bradycardia and heart block via beta-1, and bronchospasm via beta-2 — potentially fatal in asthma or COPD. It also blunts the adrenergic warning signs of hypoglycaemia, which is why it is treacherous in an insulin-treated diabetic, and it can worsen fatigue and depression in the elderly. Asthma, significant bradycardia, second- or third-degree heart block, and decompensated heart failure are all genuine contraindications to topical timolol. The mechanism sits squarely in the Autonomic Nervous System, where beta-receptor blockade is taught in full — the only twist is the route.
The other topical agents each carry their own systemic signature. Alpha-2 agonists — brimonidine and apraclonidine — can cross into the CNS; in infants and young children brimonidine causes drowsiness, hypotension, hypothermia and even apnoea and coma, so it is contraindicated in children under two and used with great caution in the young. In adults expect dry mouth, fatigue and drowsiness. Topical anticholinergics for dilation or cycloplegia — atropine above all, but also cyclopentolate — can produce a full anticholinergic toxidrome in a small child: flushing, fever, tachycardia, delirium ("hot as a hare, dry as a bone, red as a beet, mad as a hatter"); atropine's long duration makes it the worst culprit. Phenylephrine, a direct alpha-1 agonist used to dilate the pupil, can spike blood pressure — a real hazard with the 10% strength and in cardiovascular disease. And the topical carbonic anhydrase inhibitors (dorzolamide, brinzolamide) are far safer than oral acetazolamide but can still cause a metallic taste and, rarely, matter in a sulphonamide-allergic patient. All of these autonomic agents are anchored in the Autonomic Nervous System chapter.
Think of the eye's tear duct as a side door that opens directly onto the motorway of the bloodstream, with no tollbooth in between. Swallow a drug and it must pass through the liver's checkpoint — first-pass metabolism — which inspects and inactivates much of it before it reaches the main road. A drug that drains from the eye slips through the side door and merges straight into traffic, un-inspected. That is why a droplet you would never call a "dose" can behave like a small intravenous injection.
There is a simple, cheap manoeuvre that dramatically cuts systemic absorption: punctal occlusion. After instilling the drop, the patient gently presses a fingertip on the inner corner of the eye (over the tear-duct puncta) and closes the lids for one to two minutes. This blocks drainage into the nose, keeps more drug on the eye where it is wanted, and keeps far less of it out of the bloodstream where it does harm. Teaching this one-minute habit is often the difference between a safe and an unsafe topical beta-blocker in a borderline patient — and it is the reason the drug history for eye disease should always ask how the drops are actually being used.
- Eye drops reach the blood via nasolacrimal drainage, bypassing hepatic first-pass — a droplet can act systemically.
- Topical timolol → bradycardia, heart block, bronchospasm, masked hypoglycaemia; avoid in asthma/COPD/heart block/frail elderly.
- Topical brimonidine → apnoea and CNS depression in infants; contraindicated in young children.
- Topical atropine/cyclopentolate → anticholinergic toxicity (fever, delirium, tachycardia) in small children.
- Phenylephrine → hypertension (worse at 10%); topical CAIs are far milder than oral acetazolamide.
- Punctal occlusion for 1–2 minutes sharply reduces systemic absorption of any drop.
Direction two: systemic drugs that hit the eye
The traffic runs the other way too — and here the damage is often silent until it is permanent. A long list of systemic drugs injures the eye, and the ones that matter most are the ones whose damage creeps up unnoticed. Corticosteroids — systemic, and even topical or inhaled with enough exposure — raise intraocular pressure (steroid-induced glaucoma) and accelerate cataract, which is why any patient on long-term steroids needs eye monitoring. Hydroxychloroquine, taken for years in lupus and rheumatoid arthritis, deposits in the retina and causes an irreversible bull's-eye maculopathy — the reason for mandatory baseline and annual retinal screening. Ethambutol, in the standard anti-tuberculosis regimen, causes a dose-related optic neuropathy with loss of central vision and red-green colour discrimination, usually reversible only if caught early by regular visual monitoring. Amiodarone deposits in the cornea in nearly everyone (usually harmless whorl-like verticillata) but can also, less commonly, cause a genuine optic neuropathy. Each of these has its own deep dive in the Ocular Drug Toxicity subtopic, and hydroxychloroquine, amiodarone and ethambutol are revisited from the systemic side in Toxicology.
Others announce themselves more suddenly, or matter at a specific moment. Alpha-1 blockers — tamsulosin above all, prescribed for prostatic enlargement — relax the iris dilator and cause intraoperative floppy iris syndrome (IFIS): the iris billows and prolapses during cataract surgery, a serious complication the surgeon must anticipate. Crucially, the effect persists even after the drug is stopped, so every patient facing cataract surgery must be asked about a history of tamsulosin, and the surgeon warned. Topiramate (for epilepsy and migraine) can trigger acute bilateral angle-closure glaucoma through ciliary body swelling — a sudden, sight-threatening emergency in a patient who was simply started on a new tablet. Sildenafil and the other PDE5 inhibitors classically cause a transient blue-tinged vision from weak PDE6 inhibition in the retina. Vigabatrin (an antiepileptic) causes an irreversible peripheral visual field constriction that mandates field monitoring. Bisphosphonates can cause uveitis and scleritis. Systemic anticholinergics and sympathomimetics can precipitate acute angle closure in an eye with narrow angles. And isotretinoin, for acne, is a common cause of dry eye and blepharoconjunctivitis. The link to the Ocular Surface / dry-eye topic and to the Autonomic Nervous System runs through this whole list.
Corticosteroids → glaucoma + cataract. Hydroxychloroquine → bull's-eye retinopathy. Ethambutol → optic neuropathy (red-green loss). Amiodarone → corneal verticillata (± optic neuropathy). Tamsulosin → intraoperative floppy iris syndrome. Topiramate → acute angle-closure glaucoma. Sildenafil → transient blue vision. Vigabatrin → peripheral field loss. Bisphosphonates → uveitis/scleritis. Isotretinoin → dry eye. The pattern to memorise: retina (chloroquine), optic nerve (ethambutol, amiodarone), cornea (amiodarone), pressure/angle (steroids, topiramate), iris/surgery (tamsulosin), surface (isotretinoin).
The clinical lesson: the drug history is an eye exam — both ways
The practical discipline that falls out of all this is simple to state and easy to forget. First, in any patient with unexplained eye disease — a new visual field defect, a maculopathy, an optic neuropathy, a dry eye, a red eye — take a full systemic drug history, including how long each drug has been taken, because the culprit is often a tablet the patient never connects to their eyes. Second, and symmetrically, before prescribing any eye drop, ask about the body: is there asthma or COPD (timolol), heart block or bradycardia (timolol), a very young child (brimonidine, atropine), cardiovascular disease (phenylephrine)? And before cataract surgery, always ask about tamsulosin. The eye and the body share one circulation; the history has to cross the same border the drugs do. Treat every drop as a systemic drug and every systemic drug as a potential eye drug, and you will catch what a compartmentalised history misses.
- Long-term corticosteroids raise IOP (glaucoma) and cause cataract — monitor the eyes.
- Hydroxychloroquine (retina), ethambutol (optic nerve), amiodarone (cornea ± optic nerve) all need scheduled ocular screening.
- Tamsulosin causes IFIS — always warn the cataract surgeon, even if the drug was stopped.
- Topiramate, anticholinergics and sympathomimetics can precipitate acute angle-closure glaucoma.
- Sildenafil → blue vision; vigabatrin → field loss; bisphosphonates → uveitis; isotretinoin → dry eye.
- Always take a full drug history in eye disease, and ask about asthma/heart disease before prescribing drops.
- Prescribing topical timolol without asking about asthma, COPD, bradycardia or heart block — a "harmless" drop that can cause bronchospasm and dangerous bradycardia.
- Forgetting to ask about tamsulosin before cataract surgery, so IFIS ambushes the surgeon mid-operation — and assuming stopping the drug removes the risk (it does not).
- Attributing a slowly progressive maculopathy or optic neuropathy to "age" without reviewing the drug list for hydroxychloroquine, ethambutol or amiodarone.
An elderly man with well-controlled asthma is prescribed twice-daily eye drops for glaucoma. Two weeks later he presents with new wheeze and a heart rate of 46. Which drop is the most likely culprit, and what single instruction would most reduce the risk?
- Eye drops drain through the tear duct into the nose and reach the blood without hepatic first-pass, so a droplet can act like a systemic dose.
- Direction one — topical drugs with systemic harm: timolol (bradycardia, bronchospasm, masked hypoglycaemia), brimonidine (apnoea in infants), atropine (anticholinergic toxicity in children), phenylephrine (hypertension); punctal occlusion mitigates all.
- Direction two — systemic drugs that injure the eye: steroids (glaucoma/cataract), hydroxychloroquine (retinopathy), ethambutol/amiodarone (optic neuropathy), tamsulosin (IFIS), topiramate (angle closure), sildenafil (blue vision), vigabatrin (field loss), isotretinoin (dry eye).
- The rule works both ways: take a full drug history in every eye disease, and ask about asthma and heart disease before prescribing any eye drop.
- Bartlett JD, Jaanus SD. Clinical Ocular Pharmacology — systemic effects of ocular drugs and ocular effects of systemic drugs.
- Kanski's Clinical Ophthalmology: A Systematic Approach — drug-induced ocular disease and glaucoma pharmacology.
- American Academy of Ophthalmology, Basic and Clinical Science Course (BCSC) — Fundamentals and Principles of Ophthalmology; Glaucoma.
- Rang & Dale's Pharmacology / Katzung Basic & Clinical Pharmacology — autonomic drugs, beta-blockers and route-dependent systemic exposure.
- British National Formulary (BNF) — eye preparations: systemic absorption, cautions and contraindications (timolol, brimonidine).
- Royal College of Ophthalmologists — Hydroxychloroquine and Chloroquine Retinopathy: recommendations on screening.
